No. 4 • February 16 • 2022

advhealthmat.de

# ADVANCED HEALTHCARE MATERIALS

SPECIAL SECTION MEDICAL APPLICATIONS OF GLYCOMATERIALS

> Guest-Edited by Gregory A. Hudalla

ILEY-VCH

advhealthmat.de

A BAAROED EATHCARE A FRIARE

# ADVANCED HEALTHCARE MATERIALS

#### **Editorial Board**

**Executive Advisory Board** 

Kristi Anseth, University of Colorado, Boulder

Zhenan Bao, Stanford University Jason Burdick, University of Colorado, Boulder Xuesi Chen, CIAC, Changchun Chunhai Fan, Shanghai Jiao Tong University Pamela Habibović, Maastricht University Ali Khademhosseini, Terasaki Institute for Biomedical Innovation, Los Angeles Bin Liu, National University Singapore Jos Malda, University of Utrecht Nicholas Peppas, University of Texas, Austin John Rogers, Northwestern University, Evanston Jianlin Shi, Shanghai Institute of Ceramics Molly Shoichet, University of Toronto Molly Stevens, Imperial College, London Younan Xia, Georgia Institute of Technology, Atlanta Yuliang Zhao, National Center for Nanoscience and Technology, Beijing **International Advisory Board** Frank Alexis, Yachay Tech, San Miguel de Urcuquí Guillermo Antonio Ameer, Northwestern University, Evanston Frank Caruso, University of Melbourne Chunying Chen, National Center for Nanoscience and Technology, Beijing Jianjun Cheng, Westlake University, Hangzhou Jinwoo Cheon, Yonsei University, Seoul Insung Choi, KAIST, Daejon Laura De Laporte, RWTH Aachen Lola Eniola-Adefeso, University of Michigan, Ann Arbor Xiaohong Fang, Chinese Academy of Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, Beijing Eileen Gentleman, Kings College London Jürgen Groll, Universität Würzburg Zhen Gu, Zhejiang University, Hangzhou Yanglong Hou, Peking University, Beijing Jeffrey Hubbell, University of Chicago Xingyu Jiang, Southern University of Science and Technology, Shenzhen Ravi Kane, Georgia Institute of Technology, Atlanta Dae-Hyeong Kim, Seoul National University Zhuang Liu, Soochow University João F. Mano, University of Aveiro David Mooney, Harvard University, Cambridge Catherine Picart, CEA, Grenoble Buddy Ratner, University of Washington, Seattle Manuel Salmeron-Sanchez, University of Glasgow Helder Santos, University Medical Center Groningen Tatiana Segura, Duke University, Durham Orit Shefi, Bar-Ilan University, Ramat-Gan Hsing-Wen Sung, National Tsing Hua University

Shoji Takeuchi, *University of Tokyo* 

Jun Wang, South China University of Technology, Guangzhou George Whitesides, Harvard University, Cambridge Tim Woodfield, University of Otago Yi Yan Yang, A\*STAR Institute of Bioengineering and Nanotechnology, Singapore Marcy Zenobi-Wong, ETH Zurich Yu Shrike Zhang, Harvard Medical School, Cambridge

Tools

#### Submit an Article

- Browse free sample issue
- **Get content alerts**

#### Subscribe to this journal



#### **Related Titles**

Advanced Materials Advanced Functional Materials Advanced Science Advanced NanoBiomed Research Advanced Therapeutics Advanced Biology Advanced Materials Technologies Small Small Science Macromolecular Bioscience Particle & Particle Systems Characterization Nano Select

# ADVANCED HEALTHCARE MATERIALS

#### Volume 11, Issue 4

Special Section: Medical Applications of Glycomaterials

February 16, 2022 Issue Edited by: Gregory A. Hudalla

Previous Issue | Next Issue

I GO TO SECTION

**P** Export Citation(s)



#### 🔁 Free Access

# Influence of Hyaluronan Density on the Behavior of Breast Cancer Cells with Different CD44 Expression (Adv. Healthcare Mater. 4/2022)

Ana M. Carvalho, Diana Soares da Costa, Rui L. Reis, Iva Pashkuleva

First Published: 16 February 2022



#### Medical Applications of Glycomaterials

In article number 2101309 by Iva Pashkuleva and co-workers, featured in this issue's *Medical Applications of Glycomaterials* Special Section, hyaluronan gradients are developed by a two-step procedure: i) diffusional deposition of colloidal nanoparticles to obtain a gradient of gold nanoparticles and ii) immobilization of end-on-thiolated hyaluronan on this gradient. These gradients allow high-throughput screening of cells. While CD44 negative cells do not change along the gradient, the response of CD44 positive cells depend on the level of CD44 expression and hyaluronan density.





Free Access

#### An Extracellular Matrix-Liposome Composite, a Novel Extracellular Matrix Delivery System for Accelerated Tissue Regeneration (Adv. Healthcare Mater. 4/2022)

Keel Yong Lee, Huong Thanh Nguyen, Agustina Setiawati, So-Jung Nam, Minyoung Kim, Il-Gyu Ko, Won Hee Jung, Kevin K. Parker, Chang-Ju Kim, Kwanwoo Shin

First Published: 16 February 2022



#### **Wound Healing**

A new platform for the delivery of extracellular matrix (ECM) that can rapidly heal damaged tissues is developed. In article number **2101599**, Kevin K. Parker, Chang-Ju Kim, Kwanwoo Shin, and co-workers, confirm that when unfolded fibronectins are delivered by binding to small unilamellar vesicles with negative charges, they are very effective in tissue regeneration. Their findings suggest that it could be a novel ECM delivery system for ECM-based therapeutic applications, including the treatment of ulcerative colitis and inflammatory bowel disease.

Abstract | PDF | Request permissions

# Inside Back Cover

#### 🔂 Free Access

Engineered Customizable Microvessels for Progressive Vascularization in Large Regenerative Implants (Adv. Healthcare Mater. 4/2022)

Cuidi Li, Xiaoyu Han, Zhenjiang Ma, Tianyang Jie, Jinwu Wang, Lianfu Deng, Wenguo Cui

First Published: 16 February 2022



#### **Injectable Implants**

In article number <u>2101836</u> by Wenguo Cui and co-workers, an endothelial cells-laden bioink is uniformly patterned into engineered customizable microvessels with adjustable length via combining a celluar coaxial microfluidic technology and a microsurgery postdissection treatment. The customizable microvessels display excellent injectability and outstanding sprouting angiogenesis potential, and thus can be easily introduced into a variety of soft/hard regenerative scaffolds for controllable vascularization promotion.

# Back Cover

#### 🔂 Free Access

# CD47- and Integrin $\alpha 4/\beta 1$ -Comodified-Macrophage-Membrane-Coated Nanoparticles Enable Delivery of Colchicine to Atherosclerotic Plaque (Adv. Healthcare Mater. 4/2022)

Yuyu Li, Junyi Che, Lei Chang, Meng Guo, Xue Bao, Dan Mu, Xuan Sun, Xin Zhang, Wen Lu, Jun Xie

#### First Published: 16 February 2022



#### Abstract | PDF | Request permissions

#### **Modified Macrophage Membranes**

In article number 2101788 by Wen Lu, Jun Xie, and co-workers, a modified macrophage membrane-coated nanoparticle drug delivery system able to transport colchicine to atherosclerotic plaque is developed. The macrophage membrane is modified to highly express Integrin  $\alpha 4/\beta 1$  and CD47, contributing to effective accumulation of the nanoparticles in atherosclerotic plaque and attenuating foam cell formation. Intravenous injections of the hybrid system successfully reduce the lipid plaque load and improve the plaque stability.

# Masthead

#### Free Access

Masthead: (Adv. Healthcare Mater. 4/2022) First Published: 16 February 2022 PDF | Request permissions

# Reviews

**Rising Stars** 

#### Engineering DNA Nanostructures to Manipulate Immune Receptor Signaling and Immune Cell Fates

Chung Yi Tseng, Wendy Xueyi Wang, Travis Robert Douglas, Leo Y. T. Chou

First Published: 29 October 2021



DNA nanotechnology provides unique, high-resolution control over how ligands or receptors can be organized and presented to cells, offering unprecedented opportunities to elucidate and control immune receptor signaling dynamics. Understanding how receptors reorganize and interact can help inform the rational design of more effective, DNA-nanostructure-based therapies in a variety of diseases.

Abstract Full text PDF References Request permissions

#### Expanding the Repertoire of Electrospinning: New and Emerging Biopolymers, Techniques, and Applications

Liszt Y. C. Madruga, Matt J. Kipper

First Published: 17 November 2021



This review summarizes the recent developments in electrospinning technology. In particular, new fibers produced from emerging biopolymers with features that impart useful biochemical function are described, including sulfated polysaccharides (carrageenans and glycosaminoglycans), tannins and their derivatives (condensed and hydrolyzed tannins, tannic acid), and modified collagen structures. Moreover, applications of these electrospun fibers mainly in biomedical and environmental fields are highlighted.

Abstract Full text PDF References Request permissions

#### Hydrogen Sulfide: An Emerging Precision Strategy for Gas Therapy

He Ding, Jinhu Chang, Fei He, Shili Gai, Piaoping Yang

#### First Published: 17 November 2021

Hydrogen sulfide ( $H_2S$ ) emerges as a significant gaseous signaling molecule with intrinsic biochemical properties, which exerts its various physiological effects under both normal and pathological conditions. The interdependent relationship between  $H_2S$  and its corresponding chemistry, biology, and nanotherapy leads to overview  $H_2S$ -based gas therapy.



# Research Articles

#### An Extracellular Matrix-Liposome Composite, a Novel Extracellular Matrix Delivery System for Accelerated Tissue Regeneration

Keel Yong Lee, Huong Thanh Nguyen, Agustina Setiawati, So-Jung Nam, Minyoung Kim, Il-Gyu Ko, Won Hee Jung, Kevin K. Parker, Chang-Ju Kim, Kwanwoo Shin

#### First Published: 20 November 2021



This work demonstrates that negatively charged small unilamellar vesicles (SUVs) qualify as candidates for FN delivery due to their effects on the autonomous binding and unfolding of FN, which leads to increased tissue regeneration. The findings provide a new ECM-delivery platform for ECM-based therapeutic applications and suggests that properly designed SUVs may be an unprecedented FN-delivery system that is highly effective in treating UC and inflammatory bowel diseases.

#### Abstract | Full text | PDF | References | Request permissions

#### Engineered Customizable Microvessels for Progressive Vascularization in Large Regenerative Implants

Cuidi Li, Xiaoyu Han, Zhenjiang Ma, Tianyang Jie, Jinwu Wang, Lianfu Deng, Wenguo Cui

#### First Published: 19 November 2021

Engineered customizable microvessels with sprouting angiogenesis potential are fabricated to promote rapid vascularization of regenerative scaffolds after implantation. With the combination of celluar coaxial microfluidic technology and a microsurgery post-dissection treatment, ECMVs which can be introduced into a variety of soft/hard regenerative scaffolds are constructed.





# CD47- and Integrin $\alpha 4/\beta 1$ -Comodified-Macrophage-Membrane-Coated Nanoparticles Enable Delivery of Colchicine to Atherosclerotic Plaque

Yuyu Li, Junyi Che, Lei Chang, Meng Guo, Xue Bao, Dan Mu, Xuan Sun, Xin Zhang, Wen Lu, Jun Xie

First Published: 16 November 2021



A modified-macrophage-membrane (MMM)-coated nanoparticle drug delivery system able to transport colchicine to the atherosclerotic site is developed. The macrophage membrane is modified to highly express integrin  $\alpha 4/\beta 1$  and clusters of differentiation 47 (CD47), which contributes to effective accumulation of the MMM-coated colchicine-encapsulated poly(lactic-*co*-glycolic acid) nanoparticles in atherosclerotic plaque and inhibition of the clearance by circulating phagocytotic cells.

Abstract | Full text | PDF | References | Request permissions

# Degradable Hydrogel Adhesives with Enhanced Tissue Adhesion, Superior Self-Healing, Cytocompatibility, and Antibacterial Property

Yili Yang, Kai Shi, Keman Yu, Feiyue Xing, Haiwang Lai, Yingshan Zhou, Pu Xiao

First Published: 16 November 2021



Semi-interpenetrating polymer networks constructed by catechol-conjugated gelatin, iron ions, and a synthetic linear polymer can be used as degradable hydrogel adhesives with enhanced tissue adhesion, superior self-healing, good cytocompatibility, and antibacterial property. The approach to develop the multifunctional hydrogel adhesives with the multiple merits opens a new avenue in biomedical applications.

#### 🔁 Open Access

# Calcium Phosphate-Coated and Strontium-Incorporated Mesoporous Silica Nanoparticles Can Effectively Induce Osteogenic Stem Cell Differentiation

Pichaporn Sutthavas, Zeinab Tahmasebi Birgani, Pamela Habibovic, Sabine van Rijt

First Published: 08 November 2021



Mesoporous silica nanoparticles (MSNs) loaded with strontium ions (MSN<sub>Sr</sub>) and surface coated with a pH-sensitive calcium phosphate (MSN<sub>Sr</sub>-CaP) or calcium phosphate zinc layer (MSN<sub>Sr</sub>-CaZnP) are reported. It is demonstrated that the developed MSNs are taken up by human mesenchymal stromal cells and can efficiently promote osteogenesis under basic conditions, especially when multiple ions are introduced.

Abstract | Full text | PDF | References | Request permissions

# Regulation of Inflammatory Response and Osteogenesis to Citrate-Based Biomaterials through Incorporation of Alkaline Fragments

Lijie Mao, Yanrong Yin, Lixin Zhang, Xiaolei Chen, Xinqing Wang, Fangping Chen, Changsheng Liu

First Published: 19 November 2021



A novel citrate-based elastomeric with controllable pH is synthesized. The elastomeric is suitable for 3D printing and the favorable pH modulate inflammatory response and promotes cell proliferation and osteogenesis of bone defects.

Abstract Full text PDF References Request permissions

#### Extracellular Vesicles Generated Using Bioreactors and their Therapeutic Effect on the Acute Kidney Injury Model

Hyejin Kang, Yeon-hee Bae, Yongmin Kwon, Sejoong Kim, Jaesung Park

First Published: 13 November 2021

In this study, it is found that the levels of intracellular calcium ions are increased in cells cultured in bioreactors and promote extracellular vesicle secretion. Extracellular vesicles secreted in bioreactors have higher yield than those secreted in static condition and have therapeutic efficacy in an acute kidney injury model.



#### One-Step Synthesis of Multifunctional Chitosan Hydrogel for Full-Thickness Wound Closure and Healing

Shen Guo, Minghao Yao, Dan Zhang, Yuanmeng He, Rong Chang, Yikun Ren, Fangxia Guan

First Published: 17 November 2021



Multifunctional QCS/TA/Fe hydrogel based on quaternized chitosan (QCS), tannic acid (TA), and ferric iron (Fe(III)) with well antioxidant, (near-infrared light) NIR-responsive photothermal antibacterial, adhesive, conductive, self-healing, hemostasis, injectable, and biocompatible properties is prepared by one step method and used for the closure of full-thickness mouse skin model and the healing of infected full-thickness skin wound model.

Abstract Full text PDF References Request permissions

# Alleviating Oxidative Injury of Myocardial Infarction by a Fibrous Polyurethane Patch with Condensed ROS-Scavenging Backbone Units

Jieqi Xie, Yuejun Yao, Shuqin Wang, Linge Fan, Jie Ding, Yun Gao, Shifen Li, Liyin Shen, Yang Zhu, Changyou Gao

First Published: 22 November 2021



The polyurethane (PFTU) with condensed reactive oxygen species (ROS)scavenging backbone units is used to fabricate the composite fibrous cardiac patch PFTU/gelatin, which exhibits excellent antioxidant activity, ROSresponsive degradability, and presents better effect in reducing oxidative injury, cell apoptosis, inflammation, and improving cardiac functions when treating myocardial infarction in vivo.

#### Abstract | Full text | PDF | References | Request permissions

#### In Vivo Sol–Gel Reaction of Tantalum Alkoxide for Endovascular Embolization

Giho Ko, Jin Woo Choi, Kwangsoo Shin, Young Geon Kim, Taegyu Kang, Dokyoon Kim, Nohyun Lee, Hyo-Cheol Kim, Taeghwan Hyeon

First Published: 15 November 2021



Tantalum-based sol-gel precursors are presented as a novel material for permanent embolization by in vivo sol-gel reaction. New liquid embolic agent offers controllability on penetration depth, biocompatibility, and ability to drug delivery. Using these outstanding performances over clinically available counterparts, hepatocellular carcinoma in rats were successfully eliminated and life-threatening hemorrhage is prevented.

Abstract | Full text | PDF | References | Request permissions

# Pillar[5]arene-Based Acid-Triggered Supramolecular Porphyrin Photosensitizer for Combating Bacterial Infections and Biofilm Dispersion

Lei Xia, Jia Tian, Tao Yue, Hongliang Cao, Ju Chu, Haibo Cai, Weian Zhang

First Published: 17 November 2021



Abstract | Full text | PDF | References | Request permissions

#### A Glutathione Activatable Photosensitizer for Combined Photodynamic and Gas Therapy under Red Light Irradiation

Ran Wang, Xiang Xia, Yanjun Yang, Xiang Rong, Ting Liu, Zehou Su, Xiaolong Zeng, Jianjun Du, Jiangli Fan, Wen Sun, Xiaojun Peng

First Published: 23 November 2021

A photosensitizer CyI-DNBS is reported which releases SO<sub>2</sub> via glutathione activation for gas therapy. Meanwhile, the activated photosensitizer is capable of producing cytotoxic  ${}^{1}O_{2}$  for photodynamic therapy (PDT) under red light irradiation. CyI-DNBS has demonstrated highly effective therapeutic effects and can significantly inhibit the tumor growth in vivo, providing a new platform for combined PDT and gas therapy.

An acid-triggered supramolecular photosensitizer based on host–guest interaction between carboxylatopillar[5]arene (CP5) and tetrafluorophenyl porphyrin functionalized with a quaternary ammonium group (TFPP-QA) is successfully designed for efficient photodynamic anti-bacteria and biofilm eradication. The supramolecular photosensitizer possesses excellent biocompatibility and acid-responsiveness, which are beneficial to target bacteria and penetrate biofilms for effective photodynamic antibacterial therapy.



Abstract | Full text | PDF | References | Request permissions

# Guest Editorial

➡ Free Access
Medical Applications of Glycomaterials
Gregory A. Hudalla
First Published: 16 February 2022
Full text | PDF | Request permissions

# Review

#### Glycomaterials to Investigate the Functional Role of Aberrant Glycosylation in Glioblastoma

Chaitanya Tondepu, Lohitash Karumbaiah

First Published: 08 December 2021



This review article provides a detailed overview of the landscape of aberrantly modified extracellular glycans in the glioblastoma (GBM) microenvironment and their roles in mediating tumor invasion, resistance, and immunosuppression. The article also discusses design strategies to incorporate physiologically relevant glycans in glycomaterial constructs that can be used to evaluate GBM progression and treatment response.

# Research Articles

#### Influence of Hyaluronan Density on the Behavior of Breast Cancer Cells with Different CD44 Expression

Ana M. Carvalho, Diana Soares da Costa, Rui L. Reis, Iva Pashkuleva

First Published: 25 October 2021



Hyaluronan gradients are developed by a two-step procedure: i) diffusional deposition of colloidal nanoparticles to obtain a gradient of gold nanoparticles and ii) immobilization of end-on-thiolated hyaluronan on this gradient. These gradients allow high-throughput screening of cells. While CD44 negative cells do not change along the gradient, the response of CD44 positive cells depend on the level of CD44 expression and hyaluronan density.

Abstract | Full text | PDF | References | Request permissions

#### Stem Cell Microarrays for Assessing Growth Factor Signaling in Engineered Glycan Microenvironments

Austen L. Michalak, Greg W. Trieger, Kelsey A. Trieger, Kamil Godula

First Published: 20 September 2021



The present study describes the integration of glycosaminoglycan-protein conjugates into a hydrogel-supported stem cell microarray platform to analyze the activity of extracellular glycans in growth factor signaling. Such platforms can enable rapid development and optimization of functional glycomaterials for stem cell-based regenerative therapies.

#### 🔂 Open Access

# Lateral Flow Glyco-Assays for the Rapid and Low-Cost Detection of Lectins–Polymeric Linkers and Particle Engineering Are Essential for Selectivity and Performance

Alexander N. Baker, Asier R. Muguruza, Sarah-Jane Richards, Panagiotis G. Georgiou, Stephen Goetz, Marc Walker, Simone Dedola, Robert A. Field, Matthew I. Gibson



Lateral flow diagnostics typically use antibodies as the detection/capture units. In this study a "lateral flow glyco assay" is demonstrated, using glycans as both the mobile and stationary phase. The mobile phase (glycosylated gold nanoparticles) can be fine-tuned by variation of the polymer length and nanoparticle size, optimizing the signal generation toward different analytes, bringing new opportunities in biosensing.

Abstract | Full text | PDF | References | Request permissions

#### Tools

#### ~ Submit an Article Browse free sample issue Get content alerts Ó. 0 Subscribe to this journal



**Biomaterials** 

15-17 September 2022 University of Duisburg-Essen

#### **Related Titles**

**Advanced Materials Advanced Functional Materials Advanced Science** Advanced NanoBiomed Research **Advanced Therapeutics** Advanced Biology Advanced Materials Technologies Small **Small Science** Macromolecular Bioscience Particle & Particle Systems Characterization

# An Extracellular Matrix-Liposome Composite, a Novel Extracellular Matrix Delivery System for Accelerated Tissue Regeneration

Keel Yong Lee, Huong Thanh Nguyen, Agustina Setiawati, So-Jung Nam, Minyoung Kim, Il-Gyu Ko, Won Hee Jung, Kevin K. Parker,\* Chang-Ju Kim,\* and Kwanwoo Shin\*

The unfolded states of fibronectin (FN) subsequently induce the formation of an extracellular matrix (ECM) fibrillar network, which is necessary to generate new substitutive tissues. Here, the authors demonstrate that negatively charged small unilamellar vesicles (SUVs) qualify as candidates for FN delivery due to their remarkable effects on the autonomous binding and unfolding of FN, which leads to increased tissue regeneration. In vitro experiments revealed that the FN-SUV complex remarkably increased the attachment, differentiation, and migration of fibroblasts. The potential utilization of this complex in vivo to treat inflammatory colon diseases is also described based on results obtained for ameliorated conditions in rats with ulcerative colitis (UC) that had been treated with the FN-SUV complex. Their findings provide a new ECM-delivery platform for ECM-based therapeutic applications and suggest that properly designed SUVs may be an unprecedented FN-delivery system that is highly effective in treating UC and inflammatory bowel diseases.

#### 1. Introduction

Fibronectin (FN) plays an essential role in the wound healing process due to its ability to form an extracellular matrix (ECM) and to regulate cellular activities.<sup>[1]</sup> In addition to the ability to bind together and form FN fibrils, FN molecules have various recognition and binding sites in their structure, and these sites

K. Y. Lee, H. T. Nguyen, A. Setiawati, S.-J. Nam, M. Kim, K. Shin Department of Chemistry and Institute of Biological Interfaces Sogang University Seoul 04107, Republic of Korea E-mail: kwshin@sogang.ac.kr K. Y. Lee, K. K. Parker, K. Shin Disease Biophysics Group John A. Paulson School of Engineering and Applied Sciences Harvard University Cambridge 02138, USA E-mail: kkparker@seas.harvard.edu

The ORCID identification number(s) for the author(s) of this article can be found under https://doi.org/10.1002/adhm.202101599

#### DOI: 10.1002/adhm.202101599

favor interactions with various cell types, growth factors, cytokines, and other ECM proteins, such as collagen, and heparin.<sup>[2-4]</sup> Soluble FN is a folded dimeric protein whose subunits are composed of three types of repeating modules, I, II, and III with alternatively spliced V domains, which account for various isoforms of plasma FN.<sup>[5,6]</sup> Among the three modules, FN type III (FNIII) is the largest and most common repeat.<sup>[2,4]</sup> Once in contact with the cell surface, FNIII domains will be recognized by integrin proteins on the cell membrane and subsequently undergo an unfolding process caused by cell-traction forces, which induces FN fibrillogenesis.[3,7,8] Unfolding is, therefore, essential in FN functionalization, which is the target of FNbased material fabrication.<sup>[1,9]</sup> Although the cell binding sites within the FNIII module are exposed on the surface, the active

domains, which are known to be phosphorylation sites, are usually hydrophobic. These domains are buried within FNIII modules in the folded state due to hydrophobic interactions and are maintained by intramolecular ionic bonds.<sup>[10,11]</sup> Therefore, unfolding FN is crucial not only for enhancing the elasticity of fibronectin fibrils but also for exposing the buried sites that are known to display enzymatic activities and to regulate many cellular activities.<sup>[12]</sup>

A. Setiawati Department of Life Science Sogang University Seoul 02447, Republic of Korea A. Setiawati Faculty of Pharmacy Sanata Dharma University Yogyakarta 55284, Indonesia I.-G. Ko, C.-J. Kim Department of Physiology College of Medicine Kyung Hee University Seoul 02447, Republic of Korea E-mail: changju@khu.ac.kr W. H. Jung Department of Systems Biotechnology Chung-Ang University Anseong 17546, Republic of Korea

The use of soluble, compact FN has been successful in improving wound-healing treatments after being unfolded by various mechanisms.<sup>[13,14]</sup> Some examples of wounds considered thus far are diabetes- and radiation-induced cutaneous wounds in rats or mice.<sup>[15,16]</sup> Corneal epithelial wounds have also been reported to heal more quickly after having been treated using eye drops containing a soluble FN and hyaluronan combination.<sup>[17]</sup> Various efforts have also been made to develop large-scale fibronectin networks which might be adopted to facilitate the wound healing process<sup>[18-20]</sup> Nevertheless, recent reports have revealed that supplying cells with unfolded FN, compared to compact FN, improves the wound-healing efficiency more remarkably. For example, Le et al. reported an enhanced formation of FN fibrils after denaturation of FN by using urea, leading to improved platelet adhesion.<sup>[21]</sup> In 2018, Christophe et al. adopted rotary jet spinning to produce unfolded FN fibers and confirmed that its use effectively enhanced wound healing.<sup>[22]</sup> Most recently, Neale et al. demonstrated that the aligned network of unfolded FN was critical for directing fibroblast orientation and migration.<sup>[23]</sup> These studies suggest that for higher wound-healing efficiency, FN used in tissue regeneration should undergo certain procedures to induce changes in its conformation. Some methods for doing so include physical binding on different substrates, modifying surfaces with chemical groups, or using gold nanoparticles.<sup>[24-28]</sup> Although unfolded FN has been shown to perform better than compact FN, previously reported methods for unfolding FN have had limited clinical application due to the complexity of the processes required. Urea-induced FN unfolding has also been used, but it has not been widely used in in vivo experiments due to its potential cytotoxicity .[29-31]

In this study, to tackle the above issues, we demonstrate a potential FN-unfolding platform that uses negatively charged, small unilamellar vesicles (SUVs) for FN delivery. These SUVs are simply produced by using a unique composition of lipids so that the surface of the SUV not only enhances direct binding but also induces the unfolding of FN. The effects of FN delivered by our SUV system were investigated using a variety of cell-based assays to evaluate all aspects of cellular activities, including growth, differentiation, and migration. An in vivo wound-healing model of ulcerative colitis (UC) was adopted to evaluate the sufficiency of the unfolded FN that was delivered. Collectively, this FN-SUV system provides a platform that can be easily integrated into existing drug delivery systems due to its high biocompatibility, homogeneous production via spontaneous FN binding, and, provisionally, ease of formulation with a variety of drugs.

#### 2. Results

### 2.1. FN Stretched after Binding on Negatively Charged Liposomes

For critical cellular functions to be accessed, compact FN must be unfolded to expose buried domains.<sup>[32]</sup> Hence, our first effort was to determine the composition of lipids that not only enhanced the binding efficiency of FN but also induced conformational changes of FN prior to its delivery to cells. The optimized lipid composition of SUVs was found to be zwitterionic:net negative:cholesterol at a ratio of 3:2:1. An appropriate ratio of 1,2dioleoyl-sn-glycero-3-phospho-L-serine (DOPS) resulted in a net negative charge on the surface of the SUV (Figure 1a). An analogous giant unilamellar vesicle (GUV) system was developed with the same lipid composition but a hundredfold increase in size (20-30 µm on average) (Figure 1b,c). The analogous GUVs allowed us to observe the binding directly by using confocal imaging. FN tended to form insoluble aggregates when it was incubated with neutral vesicles (Figure 1b and Figure S1a, Supporting Information), but was attached evenly on the surfaces of negatively charged GUVs (Figure 1c and Figure S1b, Supporting Information). The strongly favorable and selective binding of FN to a negatively charged lipid is obvious in phase-separated GUVs with two lipid phases (Figure S2, Supporting Information). The liquid order  $(L_0)$  phase contained zwitterionic sphingomyelin, and the liquid disorder  $(L_d)$  phase contained DOPS and other unsaturated lipids, constructing the negative portion of the membrane. Under the same experimental conditions, FN was observed only in the  $L_d$  phase (green fluorescence) and not in the  $L_o$  phase of the same GUV (Figure S2b, Supporting Information). This result clearly confirmed that a negatively charged vesicle system selectively enhanced FN binding.

Direct evaluation of the binding of FN on SUVs with an appropriate size for cell delivery was much more sophisticated because SUVs (average radius of 200 nm) are remarkably smaller than GUVs (average radius of 20 µm). Images obtained from cryogenic transmission electron microscopy (cryo-TEM) showed that the SUVs incubated with FN had a membrane that was significantly thicker (thickness  $d = 8.3 \pm 0.6$  nm) than the membrane containing only lipids ( $d = 4.4 \pm 0.6$  nm) (Figure 1d,e). The thickness of the membrane comprises the lipid membrane itself, which is  $\approx$ 4–5 nm, and an additional FN layer, if any, on the membrane. This result implied that FN was, indeed, bound to the SUVs, which was observed as an increase in the membrane thickness. In addition to performing single-SUV thickness measurements, we measured the size distribution of the entire SUV population by using the dynamic light scattering (DLS) method (Figure S3, Supporting Information). The results showed that the average size of the SUV population increased from 140.3 to 178.3 nm and that the curve shifted to the right (larger size), indicating that the size of the SUV had been increased during incubation in an FN solution.

In addition to enhancing the binding of FN on the surface, negatively charged SUVs induced conformational changes. The stretching of FN was measured by using fluorescence resonance energy transfer (FRET) with FN labeled with donor-acceptor dyes (FN-DA). Four molar (4 м) guanidinium chloride (GdnHCl), one of the strongest denaturants, was used as a positive control [33] (Figure S4, Supporting Information). Figure 1f shows that the  $I_A/I_D$  ratio of FN-DA incubated with SUVs was comparable to that of FN-DA incubated in 4-м GdnHCl (0.38  $\pm$  0.06 and 0.34  $\pm$ 0.13, respectively) and was significantly lower than that of FN-DA incubated in phosphate buffered saline (PBS), which was used for SUV hydration, or sucrose, which was used for GUV hydration (1.18  $\pm$  0.2 and 1.19  $\pm$  0.05, respectively). FRET was also accomplished on GUVs coated with FN-DA; the  $I_A/I_D$  ratio of FN-DA was decreased after incubation with GUVs (from  $0.92 \pm 0.11$ to  $0.18 \pm 0.06$  after incubation) (Figure 1g,h). This result verified that stretching of FN had also occurred on the surfaces of GUVs. Taken together, the negatively charged SUV system is a suitable vehicle for delivering FN in an active, unfolded conformation.



ADVANCED HEALTHCARE MATERIALS

www.advhealthmat.de



**Figure 1.** Fibronectin binds to negatively charged vesicles, which changes its conformation. a) Illustration showing how a negatively charged surface induces binding and stretching of fibronectin (FN). b,c) Confocal images of a GUV (red) without (b) and with (c) DOPS-containing GUVs after incubation with FN (green) for 24 h (n = 5 independent experiments per group). d) Cryo-TEM images of an SUV and magnified views of its membrane (right panels) after incubation with (lower) and without FN (upper). e) Summary of the membrane thicknesses observed in (d) (n = 10 per group). f) Data from FRET showing the intensity ratio  $I_A/I_D$  observed in double-labeled FN diluted in PBS, 4 m GdnHCl, or sucrose, or incubated with SUVs (n = 3 per group). IA and ID are the acceptor and the donor fluorescence intensities, respectively. g) Single-vesicle FRET using confocal imaging showing the donor and the acceptor intensities in GUVs after 6 and 24 h of incubation with FN. h) Summary of single-vesicle FRET from (g) showing the intensity ratios  $I_A/I_D$  after 6 and 24 h of incubation with FN. h) Data represent the means  $\pm$  standard deviations (SDs)

### 2.2. FN-SUV Increased Cell Attachment and Proliferation at a Greater Rate than Soluble FN

FN has been utilized in cell and tissue cultures to strengthen cell attachment, proliferation, and migration.<sup>[25,27,34–36]</sup> We hypothesized that the conformational changes induced by binding to negatively charged SUVs would enhance the above cellular functions of FN to a greater extent than its compact form. We performed in vitro experiments using human neonatal dermal fibroblast (HDFn) cells, as they play essential roles in tissue repair. The fate of FN after having been delivered to HDFn cells was probed with either green (FN-SUV) or red (FN) fluorescent indicators. **Figure 2**a illustrates the formation of a FN matrix after having approached the surface of the HDFn cells. In both groups, FN fibrils were found to colocalize with their membrane receptor, integrin  $\alpha$ 5 (Figure 2b). However, more FN fib-

rils were produced when FN was delivered by using SUVs (Figure S5, Supporting Information). Our results suggest that FN-SUVs burst and expanded when they came into contact with the surface of the HDFn cells by the interaction between integrin  $\alpha$ 5 and FN fibrils (Figure 2c). This event was not observed on samples with aggregated FN without SUVs (data not shown), indicating that stretched FN promoted interaction with the cell surface. As we observed that SUVs unfolded FN in advance of the interaction with the cell membrane, we predicted that this would subsequently increase the adhesion of cells to the culture substrate when they are treated with FN-SUV. Figure 2d shows that trypsinized HDFn cells (green, labelled with GFP) had limited attachment to the culture dish. However, when FN-SUV was added, the number of attached and active fibroblasts (seen as spindle-shaped cells with long lamellipodia) on the disk bottom was significantly increased.[37] A quantitative compari-



ADVANCED HEALTHCARE MATERIALS www.advhealthmat.de



**Figure 2.** Delivery of FN-SUVs enhances fibrillogenesis and cell attachment. a) Schematics of FN-SUV on the HDFn surface. b) Immunostaining images illustrating binding patterns of FN fibrils (red or green) on HDFn surfaces (n = 3 independent experiments per group). White represents the integrin  $\alpha$ 5-FITC antibody. c) Images of 7.5-min time intervals showing the untangling process of FN-SUV bundles on the surfaces of HDFn cells (n = 3). d) Live-cell images showing changes in the morphologies of HDFn cells after 20 h of incubation with PBS (Ctrl), FN, or FN-SUVs (n = 3 independent experiments per group). e) Attachment rate of HDFn cells quantified by the area of the cells attached to the dish's surface (n = 3 per group). f) Live cell images showing the areas of the FN matrix formed on the surfaces of HDFn cells after incubation with FN or FN-SUVs (n = 5 independent experiments per group).

son of cell attachment among the experimental groups was performed by calculating the total area of attached cells, as shown in Figure 2e. Moreover, the area of the FN matrix was significantly greater when FN was delivered by SUVs, implying enhanced extracellular matrix formation (Figure 2f and Video S4, Supporting Information). Although FN promoted cell attachment, stretched FN made the surfaces of GUVs unfavorable for bacteria, particularly Staphylococcus aureus (S. aureus), an organism that often causes opportunistic infections on skin and leads to tissue damage, as described in a previous study.<sup>[38]</sup> S. aureus was incubated with different types of GUVs (Figure S6 and Videos S1-S3, Supporting Information). A large number of bacteria (white) were found on collagen-coated GUVs (COL-GUVs). In contrast to the case with the bare lipid GUVs, the bacteria were hardly present on the FN-coated GUVs, suggesting that using the stretched FN as a wound healing agent had advantages in preventing unwanted bacterial infection during the healing process.

#### 2.3. SUV-Induced Stretched FN Promoted Cell Migration

When tissue is injured, released cytokines attract fibroblasts from the surrounding area.<sup>[1]</sup> During this time, fibroblasts are activated and migrate towards the injured area with the recruitment of ECM proteins including FN.<sup>[39,40]</sup> We tested whether the stretching of FN would promote the migration rate of fibroblasts, as it has been shown to enhance ECM formation. Figure 3a shows representative images cut from Videos S5-S7, Supporting Information, illustrating the movements of HDFn-GFP cells as a function of time. Single cells were tracked, and the average migration speeds (micrometer per minute) were compared among groups. As we expected, the migration speed increased when SUVs (green circles) were used for FN delivery (Figure 3a,b). This enhancement may result from the formation of a denser FN matrix, which facilitates cell adhesion and migration. The expansion of the FN matrix over time can be seen clearly in Figure S7 and Video S11, Supporting Information.





**Figure 3.** FN-SUV treatment accelerates the migration rate of HDFn cells. a) Representative images tracking the migration speed of single HDFn cells in the control (Ctrl), FN- and FN-SUV-treated groups. b) Summary of the single-cell migration speeds in the control, FN- and FN-SUV-treated HDFn cells (n = 25, from 5 independent experiments). c) in vitro scratch assays were performed in the control, FN- and FN-SUV-treated HDFn cells to compare the rates of migration. Representative images were extracted from the time series at 0 and 12.5 h. d) Results of quantitative analyses of the recovery areas covered by migrated cells as described in (c). Data were collected from the same optical field at 1 h time intervals over 15 h (n = 4 independent experiments).

In vitro scratch assays were used to assess the cell migration speed to evaluate cell migration.<sup>[41]</sup> To ensure the reproducibility of the experiments, we set up an incubation chamber in the confocal microscope system and continuously observed a specific injured area for at least 16 h. Representative images at 0 and 12.5 h for each group are shown in Figure 3c; the corresponding timelapse images are shown in Videos S8-S10, Supporting Information. The results revealed that among the experimental groups, the gap closed at the highest rate in the FN-SUV-treated group, with  $60.3 \pm 4.3\%$  of the gap area being covered by HDFn cells after 15 h compared to only  $33.5 \pm 4.2\%$  in the FN-treated group (Figure 3d) with higher directionality and more elongated morphology (Figure S8, Supporting Information). Insignificant proliferation among all groups was observed during the first 24 h, which showed that the cell migration assays were unbiased, with minimal contribution from cell proliferation (Figure S9, Supporting Information).

### 2.4. FN-SUV Improved Wound Healing in Rats with Ulcer Colitis More Significantly than Compact FN

The healing effects of FN in vivo were described previously by using a wide range of wound models in different species, such as rabbits, mice, and guinea pigs.<sup>[16,42,43]</sup> Existing evidence from previous studies indicates that in inflammatory bowel-related diseases, such as ulcerative colitis (UC) and Crohn's disease, the level of FN in the plasma is decreased significantly.<sup>[9,44]</sup> In this present study, the healing performance of FN-SUVs was further assessed in vivo using an UC model for rats. An approved protocol using 4% acetic acid was applied to induce UC in the colon, followed by a 10-day treatment strategy with either FN or FN-SUVs (Figure S10, Supporting Information). After treatment, the entire colons of the rats were removed to compare changes in morphology, wet weights, and various tissue damage markers (**Figure 4**a). As shown in Figure 4b, the FN-SUV-treated group

SCIENCE NEWS \_\_\_\_\_\_





**Figure 4.** FN-SUV treatment improves the healing process of acid-induced ulcers in rat colons. a) Hypothesized schematic of FN-SUV treatment in the rat colon. b) Gross morphologies of the intestines removed from the rats after 10 days of treatment. In the control group, the healthy colon wall can be seen to be thin and smooth with no mucus while in the colitis-induced groups, the wall of the colon is swollen and filled with blood and mucus. Various degrees of colitis can be seen among the different treatments. c,d) Ulcer score and stool score of the control and the colitis-induced groups as described in (a) (n = 10 per group). e) Colon wet weight of the control and the colitis-induced groups as described in (a) (n = 10 per group). e) values were calculated using Student's *t*-tests. f,g) Expression levels of the inflammatory indicators COX-2 (n = 5 per group) (d) and iNOS (n = 6 per group) (e). d–g) Error bars indicate the SDs.

ADVANCED HEALTHCARE MATERIALS www.advhealthmat.de

showed remarkably thinner and smoother colon walls with less mucus (less tissue damage) than the FN-treated group. Moreover, mesalamine- and FN-SUV-treated groups had decreased the ulcer scores and stool score as a result of the improvements of histological alterations, including ulceration, mucosal atrophy, submucosal edema, and inflammatory cells infiltration (Figure 4c,d and Figure S11, Supporting Information). In addition, FN-SUVtreated colons had significantly lower wet weights than those treated with FN alone, indicating that SUV-FN treatment reduced inflammation and swelling in the colons (Figure 4e).

Colon tissues after either FN or FN-SUV treatment were further analyzed semi-quantitatively for inflammatory markers, including tumor necrosis factor (TNF)- $\alpha$ , interleukin (IL)-1 $\beta$ , IL-6, cyclooxygenase (COX)-2, and inducible nitric oxide synthase (iNOS). However, the differences in the levels of tumor necrosis factor (TNF)- $\alpha$ , IL-1 $\beta$ , and IL-6 expressions between the FN and the FN-SUV groups were insignificant (Figure S12, Supporting Information) whereas COX-2 and iNOS expressions were downregulated in rats treated with FN-SUV, suggesting that the unfolding of FN via the SUV may expose domains that communicate with cells via these two pathways (Figure 4f,g).<sup>[45,46]</sup> The inhibitions of the COX-2 and the iNOS expressions in our in vivo model clearly showed that inflammation was effectively decreased in the experimental UC model when the FN-SUV treatment was administered.<sup>[47]</sup>

#### 3. Discussion

Many attempts have been made to unfold FN prior to its reaching the cell. However, an appropriate approach to unfolding FN for tissue regeneration applications is still a challenge. The unfolding of FN requires the breakage of intramolecular bonds and hydrophobic interactions, which can be induced by using either chemicals<sup>[21,33]</sup> or mechanical forces.<sup>[10,22]</sup> The pH or salt concentration can induce the stretching of FN, but this reversible change is hard to maintain for cell delivery. Moreover, the solution must be similar to the physiological environment. The improper removal of a denaturant will otherwise potentially result in negative effects on live cells and tissues.<sup>[33]</sup>

The adsorption and unfolding facilitated by chemical modifications raise a risk of cytotoxicity.[24-27] On the other hand, approaches using mechanical forces to unfold FN usually exploit solid substrates and polymers with low biocompatibility. The most promising approach might be to produce nanofibers from soluble FN by using mechanical forces.<sup>[22,48]</sup> However, the FN nanofiber production remains challenging, as the use of the fabrication technique may not always be possible in laboratories. Nonetheless, FN nanofibers are more appropriate for dressing materials and cutaneous wound treatment than for the treatment of bowel diseases. Despite major efforts to deliver ECM or FN to damaged tissues via surface-modified substrates, the fabrication of these materials remains very complex, and these substrates usually have to be removed from the body after having been applied, which is not appropriate for deep, closed wounds.<sup>[49,50]</sup> In contrast, negatively charged SUVs are highly biocompatible, which have been used for drugs and mRNA-base vaccines.<sup>[51-53]</sup> All the lipids (e.g., DOPC, DOPS, and DOPE) used in this research have been clinically approved and are being commercialized.<sup>[54]</sup> Accordingly, we managed to develop a negatively charged SUV system that had negligible toxicity and could safely deliver the desired therapeutic materials.<sup>[51,55]</sup> In addition, the preparation of self-assembled SUVs in an aqueous solution, followed by the autonomous binding and unfolding of FN, was much simpler and afforded higher yields than any other method.

The adsorption and unfolding of FN on liposomes were reported by Halter et al. in 2005.<sup>[56]</sup> Both gel-phase and liquid-phase liposomes were considered for FN selective binding, but only liposomes composed of lipids that had high melting temperature  $(T_{\rm m})$  or existed in the gel phase at room temperature, such as DPPC ( $T_{\rm m}$  = 41 °C) or DSPC ( $T_{\rm m}$  = 55 °C), were observed to bind and unfold FN effectively.<sup>[56]</sup> Apart from gel-phase liposomes, we have sufficient experimental evidence to prove that FN is able to bind and unfold on liquid-phase liposomes composed of lipids with  $T_{\rm m}$  < 0 °C under the condition that a negatively charged lipid (DOPS) is added. Due to the low  $T_{\rm m}$  values of the lipids used, the fabrication of negatively charged SUVs is simplified and can be performed at room temperature. Nevertheless, the in vitro and vivo effects of FN-SUV have not been characterized, although the adsorption and unfolding of FN on liposomes was reported in detailed in Halter's study. Therefore, the negatively charged SUV system has significant advantages over previous FN-based wound healing materials in terms of fabrication, cytotoxicity, and biocompatibility.

#### 4. Conclusions

Collectively, we confirmed that negatively charged SUVs could effectively unfold FN bound to their surfaces. Subsequently, the SUVs enhanced the effects of FN on HDFn migration and proliferation. In vivo experiments showed that rats with UC that had been treated with FN-SUVs improved faster than rats treated with only soluble FN. The abundant amount of FN in the plasma is an advantage of using FN as a potential tissue regeneration material.<sup>[1,9,44]</sup> FN also possesses an exceptional property for wound healing, as stretched FN disrupts the binding of *S. aureus*, a common cause of infections in humans.<sup>[38]</sup>

We conclude that negatively charged SUVs are ideal vehicles for functional FN delivery. The system has the capability to carry and unfold FN with high biocompatibility and safety and can be used as a platform for incorporating drugs that accelerate wound healing. Further studies are expected to discover the mechanisms underlying the efficacy of the SUV-FN delivery system.

#### 5. Experimental Section

Preparation of Small Unilamellar Vesicles (SUVs) with Negatively Charged Surfaces: Multilamellar liposomes were first prepared by blending DOPC:DOPE:DOPS:cholesterol in a ratio of 2:1:2:1 to make a mixture with a total concentration of 5 mg of lipids per milliliter in chloroform. One milliliter of the lipid blend in a black glass vial was blown dry using N<sub>2</sub> gas for 2 h to completely remove the solvent. The dried lipids were then rehydrated with  $1 \times PBS$  (pH 7.4) by using a vortex mixer at room temperature for 60 min. The lamellarity of the liposomes was reduced by using 5 cycles of freezing in liquid nitrogen and thawing in a water bath at 40 °C to break down the outer bilayers. Finally, the vesicles were extruded by using a mini-extruder set (Avanti, Inc.) to pass them through a 200-nm membrane filter 11 times. The day before experiment, a fibronectin (FN) solution that had been previously diluted in deionized water was added to make an FN or FN-SUV solution with a final concentration of 10  $\mu g~mL^{-1},$  followed by incubation at 37  $^\circ C$  overnight.

www.advancedsciencenews.com

Preparation of Giant Unilamellar Vesicles (GUVs): A lipid mixture with a composition of either DOPC:DOPE:DOPS:cholesterol (2:1:1:1 molar ratio) for negatively charged GUVs or DOPC:DOPE:cholesterol (2:1:1) for neutrally charged GUVs was prepared with a concentration of  $1 \text{ mg mL}^{-1}$ . Approximately 30 µL of the lipid mixture was deposited on ITO glass (30-Ohm sheet resistance) and quickly dried by using flowing N<sub>2</sub> gas. The lipids were continuously dehydrated in a vacuum desiccator for  $\approx 1$  h. A silicon ring with a thickness of 1 mm was inserted between two ITO glass slides to make space for the hydrate solution. For observations under a light microscope, the lipids were rehydrated with an inner solution containing 200-mm sucrose and 2-mm MES (pH 4.2) and were later diluted with an outer solution containing 200-mm glucose and 2-mm MES (pH 4.2). Before confocal microscopy, a fibronectin (FN) solution that had been previously diluted in deionized water was added to make an FN-GUV solution with a final concentration of 10  $\mu$ g mL<sup>-1</sup>, followed by incubation at 37 °C overnight. GUVs were imaged by using confocal microscopies (Leica SP8 and ZEISS LSM 710) at the Bioimaging Center of the Advanced Bio-Interface Core Research Facility, Sogang University.

*Preparation of Fibronectin (FN)*: Fibronectin was in powder form before being diluted into deionized water to make a FN stock solution at concentration of 1 mg mL<sup>-1</sup>. FN solution was stored at -20 °C or longterm storage and thawed slowly at 4 °C before use.

FN Conjugation for Fluorescence Resonance Energy Transfer (FRET) Analysis: Fibronectin (FN) was subsequently labeled with Alexa-546 C5 maleimide on its cysteine residues and with Alexa-488 NHS succinimidyl ester on its lysine residues. Lyophilized FN diluted with PBS to a concentration of 1 mg mL<sup>-1</sup> was denatured in the chaotropic agent guanidine hydrochloride (GdnHCl, 8 M) at a ratio of 1:1 (v/v) and then incubated with Alexa 546 maleimide at a molar ratio of 1:30. Excess fluorescence dye was removed through dialysis by using a slide-A-lyzer dialysis cassette with a 10000 Dalton MW cut-off in 0.1-м sodium bicarbonate (NaHCO<sub>3</sub>) at pH 8.5. The buffer was changed twice every 2 h before being stored overnight at 4 °C. The initial conformation of labeled FN was confirmed using spectrofluorometry. Afterwards, the labeled FN was incubated for one hour with Alexa 488 NHS succinimidyl ester at a ratio of 1:70 (mol/mol). Doubly labeled FN with a donor and an acceptor dye (FN-DA) was separated from the free dyes by using a PD-10 column (pre-equilibrated with PBS). The ratio of the donor intensity to the acceptor intensity per FN dimer  $(I_A/I_D)$ was determined by measuring the fluorescences of FN-DA at 280, 496, and 556 nm. For long-term storage, FN-DA was stored in 10% glycerol at -80 °C.

Characterization of FN-SUV Incorporation by Using Cryogenic Transmission Electron Microscopy (Cryo-TEM): FN was incubated overnight with preformed SUVs at a ratio of 1:5 (w/w). Immediately after incubation, samples of either SUVs or FN-SUVs were preserved by vitrification and supported by Quantifoil (R 2/2, 400-mesh holey-carbon grid, Quantifoil Micro Tools). Vitrified samples were prepared by applying a 3-µL drop of sample suspension to a cleaned grid, blotting away the excess with filter paper, and immediately plunging the grid into liquid ethane. Grids were stored under liquid nitrogen until being transferred to the transmission electron microscope for imaging. Electron microscopy was performed using a Talos L120C electron microscope (FEI, Hillsboro, OR, USA) operating at 120 kV. Vitreous ice grids were transferred into the electron microscope by using a cryostage that maintained the grids at a temperature below -170 °C. An image of each grid was acquired on multiple scales to assess the overall distribution of the specimen. Images were collected using a  $4k \times 4k$  Ceta CMOS camera at a search magnification of 5000 and a final magnification of 29 000 to 280 000 at an underfocus of  $\approx\!2.5\,\mu m.$  After the identification of potentially suitable target areas for imaging at lower magnifications, pairs of highly magnified images were acquired using the UI V1.6 Talos software. ImageJ software was used to analyze the intralamellar distances in the original, high-resolution images collected using the microscope (4096  $\times$  4096 pixels).

Fluorescence Resonance Energy Transfer (FRET) Analysis: The donor fluorophores Alexa NHS-488 labelled lysine residues and acceptor fluorophores (Alexa maleimide-546) labelled cysteines on FN modules on FN. There are five lysine and two cysteine residues in each FN monomer. For every FN-FRET batch, we calculated the ratio of donors to acceptors per FN dimer by measuring the absorbances of FN-DA at 280, 496, and 556 nm and using published extinction coefficients for dyes.<sup>[57–59]</sup> For each dimer molecule used in this study, we calculated an average labeling ratio of  $8.5 \pm 0.5$  donors and  $3.3 \pm 0.84$  acceptors per FN dimer. Two acceptor-cysteines are presented in FNIII7 and FNIII15 on each monomer (for molecules for dimer). In native FN (folded), FNIII module locates in cryptic domain stabilizing through ionic interaction between arms; while, in extended FN, FNIII module loss of secondary structure leading distance increase of donor and acceptor (>12 nm) and decrease the energy transfer.

The fluorescence intensity of FN-DA was measured using a standard fluorescence spectrophotometer (Hitachi F-7000) with excitation of the donor at 488 nm. The positive controls were measured using a series of GdnHCl concentrations from 0 to 4  $\mu$ . The data from FRET measurements over a range of denaturant concentrations was used to plot the correlation of the FRET efficiency with the degree of FN unfolding.<sup>[60]</sup> FN-DA was incubated overnight with preformed SUVs at a ratio of 1:5 (w/w) with gentle rocking to enhance the binding. Then, cryo-TEM and FRET were exploited to characterize the incorporation and the unfolding SUVs in solution, and the negative control was measured using FN-DA in PBS at the same concentration as in the FN-SUV sample, but without SUVs.

Colocalization, Attachment Area, and Fibril Formation Imaging: HDFn cells were cultured in DMEM (FBS 10%, 1% Pen-Strep). For integrin observation, FITC-conjugated integrin  $\alpha$ 5 antibody was used. FN was diluted in PBS and used at a concentration of 10 µg mL<sup>-1</sup>. For cell attachment experiments, HDFn-GFP cells were detached using trypsin-EDTA when the confluence had reached 80% and were then transferred to a new culture dish, treated with non-labeled FN and imaged every hour in an on-stage incubator. For quantification of the area of the FN fibrils, HDFn-GFP cells were treated with lissamine-rhodamine-labeled FN and imaged. In-situ images as a function of time were taken using an on-stage incubator with CO<sub>2</sub> and temperature control. Images and videos were processed using ImageJ and Zen software.

*In Vitro Scratch Assay*: In migration experiments, GFP-HDFn cells were cultured in T75 flasks to reach a confluence of 80–90% and were then transferred to 35-mm dishes for continuous culturing over 24 h with 10% FBS for attachment. When cells had formed a confluent monolayer, the medium was replaced with low-serum DMEM (0.4% FBS) every 24 h to minimize the effects of proliferation on the migration speed and to avoid unexpected apoptosis.<sup>[41]</sup> The distance that a single cell moved was tracked using Image].

A scratch mimicking a wound was created using a p200 pipette tip by scraping a straight line across the center of the dish. Cell debris was then washed away gently with 2 mL of low-serum medium before being supplemented with either PBS, FN, or FN-SUV. The final concentration of FN or FN-SUV solution is 10  $\mu$ g mL<sup>-1</sup> in all experiments, unless otherwise stated. The 35-mm dish was placed in a stage-top incubator (Zeiss, USA) with a CO<sub>2</sub> supply and a controlled temperature of 37 °C to obtain the same optical field during the image acquisition. Images of GFP-HDFn cells migrating to the scratch were recorded using confocal microscopy (ZEISS LSM 710, USA) in a time series mode at 1 h intervals for at least 15 h.

Ulcerative Colitis Rat Model: We followed the Guidelines for the Care and Use of Animals approved by the National Institute of Health Council for the management and use of animals for laboratory tests. The experimental design was approved by the Institutional Care and Use Committee of Kyung Hee University (KHUASP(SE)-15-085). Rats were divided into the following five groups (n = 10 in each group): healthy group (negative control), ulcerative colitis (UC)-induced group (positive control), UCinduced/mesalamine-treated group, UC-induced/FN-SUV-treated group, and UC-induced/FN-treated group.

*Induction of Ulcerative Colitis by Using Acetic Acid*: Ulcerative colitis (UC) was induced by using acetic acid, as previously described.<sup>[61]</sup> The rats were anesthetized with Zoletil 50 (10 mg kg<sup>-1</sup>; Vibac Laboratories, Carros,





France). Animals were fasted for 48 h for UC preparation. A stainless-steel feeding needle (round tip, 16 gauge) was then carefully inserted into the colon of a rat with the tip being 8 cm proximal to the anus. Then, 4% acetic acid (Sigma Chemical Co., St. Louis, MO, USA) in 0.9% saline (1.0 mL) was injected into the lumen of the colon. The control group underwent intracolonic injection with saline instead. The rats were maintained in a supine Trendelenburg position for 5 min to prevent leakage of the injected acetic acid solution.

UC Treatment: The UC treatments were administered three days after acetic acid injection. The dosages for the groups were as follows: mesalamine (4 g/100 mL, Asacol Enema, Tillotts Pharma, AG, Swiss), FN-SUVs (20  $\mu$ g mL<sup>-1</sup> FN, 100  $\mu$ g mL<sup>-1</sup> SUVs), and FN (20  $\mu$ g mL<sup>-1</sup>). For drug administration, the rats were confined in an acrylic cylinder (diameter: 6 cm, length: 20 cm, height: 10 cm) without anesthesia. A stainless-steel feeding needle (round tip, 16 gauge) with a syringe was then carefully inserted through the anus into the damaged site. Then, each drug (1.0 ml) was injected into the lumen of the colon once a day for 10 days after induction of UC.

*H*@*E* Staining and Evaluated of Ulcer Score: Histological changes in colon tissues were detected by H&E staining as previously described by Jeon et al.<sup>[62]</sup> The slides were immersed in Mayer's hematoxylin (DAKO, Glostrup, Denmark) for 30 s and then rinsed with tap water until clean. The slides were then immersed in eosin (Sigma Chemical Co., St. Louis, MO, USA) for 10 s and rinsed again with water. The slides were dried at room temperature and then immersed in 95% ethanol twice, in 100% ethanol twice, in 50% ethanol and 50% xylene twice, and in 100% xylene twice. The slides were covered with coverslips of Permount (Fisher Scientific, New Jersey, NJ, USA). The parameters evaluated for ulcer score were: histological ulceration, mucosal atrophy, submucosal edema, and inflammatory cells infiltration. Each parameter was scored on a scale from zero (normal) to 3 (severe damage) according to the criteria described by Mehrabani et al. .<sup>[63]</sup> Total ulcer score was calculated by summing up individual scores for each rat..<sup>[63,64]</sup>

Western Blotting: Colon tissues were homogenized on ice, lysed with lysis buffer, and then centrifuged at 14 000 rpm for 30 min. The amount of protein in each sample was quantified using a Bio-Rad colorimetric protein assay kit (Bio-Rad, Hercules, CA, USA). Sodium dodecyl sulfatepolyacrylamide gels were used to separate proteins (30 µg), after which the separated proteins were transferred onto nitrocellulose membranes. Goat COX-2 antibody (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse iNOS antibody, and mouse  $\beta$ -actin antibody (1:1000; Santa Cruz Biotechnology) were used as the primary antibodies. Horseradish peroxidase-conjugated anti-mouse antibodies (1:2000; Vector Laboratories, Burlingame, CA, USA) for iNOS,  $\beta$ -actin, and COX-2 were used as secondary antibodies. Membrane transfer was conducted at 4 °C by using a cold pack and pre-chilled buffer. An enhanced chemiluminescence (ECL) detection kit (Santa Cruz Biotechnology) was used for band detection. Molecular Analyst (version 1.4.1, Bio-Rad) was used to analyze the detected bands.

Data Analysis: All of the images, except for the in vivo experiments, were analyzed using either ImageJ (1.51) or Zen software (2.3 SP1, Black edition). Migration of each cell was analyzed by using the plug-in Mtrack2 in ImageJ. The recovery areas were quantified using ImageJ. For cell area study, the intensity of GFP-expressing HDFn per area was calculated from the confocal images by using ImageJ. The orientation in degrees of grey-scale GFP-expressing HDFn images were analyzed through the OrientationJ plug-in ImageJ software.

Using the Image-Pro plus computer-assisted image analysis system (Media Cybernetics Inc., Silver Spring, MD, USA), the area of UC in each sample was measured with help of a light microscope (Olympus, Tokyo, Japan). For relative quantification, the results in the control group of western blot were set as 1.00.

#### **Supporting Information**

Supporting Information is available from the Wiley Online Library or from the author.

#### Acknowledgements

K.Y.L and H.T.N. contributed equally. This work was supported by the Samsung Science and Technology Foundation under Project Number SSTFBA180112010. International collaboration was in part conducted through the Sogang-Harvard-SDU Biohybrid Center.

#### **Conflict of Interest**

The authors declare no conflict of interest.

#### Data Availability Statement

Research data are not shared.

#### **Keywords**

extracellular matrix, fibronectin, fibronectin delivery, small unilamellar vesicles, ulcerative colitis, wound healing

Received: August 4, 2021 Revised: October 26, 2021 Published online:

- [1] W. S. To, K. S. Midwood, Fibrog. Tissue Repair 2011, 4, 21.
- [2] M. Gao, D. Craig, V. Vogel, K. Schulten, J. Mol. Biol. 2002, 323, 939.
- [3] C. A. Lemmon, S. H. Weinberg, Sci. Rep. 2017, 7, 18061.
- [4] E. P. Gee, D. Yuksel, C. M. Stultz, D. E. Ingber, J. Biol. Chem. 2013, 288, 21329.
- [5] L. M. Maurer, W. Ma, D. F. Mosher, Crit. Rev. Biochem. Mol. Biol. 2015, 51, 213.
- [6] J. A. Paten, C. L. Martin, J. T. Wanis, S. M. Siadat, A. M. Figueroa-Navedo, J. W. Ruberti, L. F. Deravi, *Chem* 2019, 5, 1930.
- [7] J. E. Schwarzbauer, J. L. Sechler, *Curr. Opin. Cell Biol.* **1999**, 11, 622.
- [8] J. Ulmer, B. Geiger, J. P. Spatz, Soft Matter 2008, 4, 1998.
- [9] H. W. Verspaget, I. Biemond, C. F. Allaart, H. van Weede, I. T. Weterman, H. G. Gooszen, A. S. Pena, C. B. Lamers, *Hepato-gastroenterology* **1991**, *38*, 231.
- [10] M. L. Smith, D. Gourdon, W. C. Little, K. E. Kubow, R. A. Eguiluz, S. Luna-Morris, V. Vogel, *PLoS Biol.* 2007, 5, e268.
- [11] K. J. Johnson, H. Sage, G. Briscoe, H. P. Erickson, J. Biol. Chem. 1999, 274, 15473.
- [12] V. Vogel, Annu. Rev. Biophys. Biomol. Struct. 2006, 35, 459.
- [13] O. S. Ejim, G. W. Blunn, R. A. Brown, Biomaterials 1993, 14, 743.
- [14] J. Patten, K. Wang, Adv. Drug Delivery Rev. 2021, 170, 353.
- [15] Z. Qiu, A. H. Kwon, Y. Kamiyama, J. Surg. Res. 2007, 138, 64.
- [16] M. B. Johnson, B. Pang, D. J. Gardner, S. Niknam-Benia, V. Soundarajan, A. Bramos, D. P. Perrault, K. Banks, G. K. Lee, R. Y. Baker, G. H. Kim, S. Lee, Y. Chai, M. Chen, W. Li, L. Kwong, Y. K. Hong, A. K. Wong, *Sci. Rep.* **2017**, *7*, 3876.
- [17] M. Nakamura, T. Nishida, M. Hikida, T. Otori, *Curr. Eye Res.* **1994**, *13*, 385.
- [18] S. Ahn, L. F. Deravi, S. J. Park, B. E. Dabiri, J. S. Kim, K. K. Parker, K. Shin, Adv. Mater. 2015, 27, 2838.
- [19] S. Jordahl, L. Solorio, D. B. Neale, S. McDermott, J. H. Jordahl, A. Fox, C. Dunlay, A. Xiao, M. Brown, M. Wicha, G. D. Luker, J. Lahann, Adv. Mater. 2019, 31, 1904580.
- [20] N. Pernodet, M. Rafailovich, J. Sokolov, D. Xu, N. L. Yang, K. McLeod, J. Biomed. Mater. Res., Part A 2003, 64, 684.
- [21] P. Le, S.-N. Mai-Thu, T.-H. Nguyen, T. Vo Van, K. Huynh, presented at IFMBE Proc., Ho Chi Minh, Vietnam, May 2017.

#### ADVANCED SCIENCE NEWS



#### www.advhealthmat.de

- www.advancedsciencenews.com
- [22] C. O. Chantre, P. H. Campbell, H. M. Golecki, A. T. Buganza, A. K. Capulli, L. F. Deravi, S. Dauth, S. P. Sheehy, J. A. Paten, K. Gledhill, Y. S. Doucet, H. E. Abaci, S. Ahn, B. D. Pope, J. W. Ruberti, S. P. Hoerstrup, A. M. Christiano, K. K. Parker, *Biomaterials* **2018**, *166*, 96.
- [23] D. B. Neale, A. J. Muñiz, M. S. Jones, D. H. Kim, J. M. Buschhaus, B. A. Humphries, W. Y. Wang, B. M. Baker, J. E. Raymond, L. Solorio, G. D. Luker, J. Lahann, *Small Struct.* **2021**, *2*, 2000137.
- [24] R. J. Klebe, K. L. Bentley, R. C. Schoen, J. Cell. Physiol. 1981, 109, 481.
- [25] M. Lin, H. Wang, C. Ruan, J. Xing, J. Wang, Y. Li, Y. Wang, Y. Luo, Biomacromolecules 2015, 16, 973.
- [26] G. K. Toworfe, R. J. Composto, C. S. Adams, I. M. Shapiro, P. Ducheyne, J. Biomed. Mater. Res., Part A 2004, 71, 449.
- [27] A. L. Koenig, V. Gambillara, D. W. Grainger, J. Biomed. Mater. Res., Part A 2003, 64, 20.
- [28] A. W. Feinberg, K. K. Parker, Nano Lett. 2010, 10, 2184.
- [29] S. Patel, A. F. Chaffotte, F. Goubard, E. Pauthe, *Biochemistry* **2004**, *43*, 1724.
- [30] J. A. Weston, K. L. Hendricks, Proc. Natl. Acad. Sci. U. S. A. 1972, 69, 3727.
- [31] A. D. Glinos, G. N. Bardi, K. C. Dermitzaki, S. A. Perez, M. J. Talieri, J. Natl. Cancer Inst. 1983, 71, 1211.
- [32] R. Mezzenga, M. Mitsi, Biomacromolecules 2019, 20, 55.
- [33] O. D. Monera, C. M. Kay, R. S. Hodges, Protein Sci. 1994, 3, 1984.
- [34] A. J. Garciá, M. a. D. Vega, D. Boettiger, Mol. Biol. Cell 1999, 10, 785.
- [35] B. Lariviere, M. Rouleau, S. Picard, A. D. Beaulieu, Wound Repair Regener. 2003, 11, 79.
- [36] Y. X. Liao, Z. P. Zhang, J. Zhao, J. P. Liu, Cell. Physiol. Biochem. 2018, 48, 1382.
- [37] A. R. Toledo-Piza, E. Nakano, R. E. Rici, D. A. Maria, *Cell Proliferation* 2013, 46, 97.
- [38] M. Chabria, S. Hertig, M. L. Smith, V. Vogel, Nat. Commun. 2010, 1, 135.
- [39] L. E. Tracy, R. A. Minasian, E. J. Caterson, Adv. Wound Care 2016, 5, 119.
- [40] R. A. Clark, J. M. Lanigan, P. DellaPelle, E. Manseau, H. F. Dvorak, R. B. Colvin, J. Invest. Dermatol. 1982, 79, 264.
- [41] C. C. Liang, A. Y. Park, J. L. Guan, Nat. Protoc. 2007, 2, 329.
- [42] A. H. Kwon, Z. Qiu, Y. Hiraon, Surgery 2007, 141, 254.

- [43] F. Grinnell, R. E. Billingham, L. Burgess, J. Invest. Dermatol. 1981, 76, 181.
- [44] R. Kochhar, N. Kumar, V. Singh, M. K. Goenka, S. K. Mehta, Natl. Med. J. India 1991, 4, 108.
- [45] J.-d. Luo, A. F. Chen, Acta Pharmacol. Sin. 2005, 26, 259.
- [46] A. Futagami, M. Ishizaki, Y. Fukuda, S. Kawana, N. Yamanaka, *Lab. Invest.* 2002, 82, 1503.
- [47] G. Guo, W. Shi, F. Shi, W. Gong, F. Li, G. Zhou, J. She, J. Biochem. Mol. Toxicol. 2019, 33, e22400.
- [48] J. M. Szymanski, E. N. Sevcik, K. Zhang, A. W. Feinberg, *Biomater. Sci.* 2017, 5, 1629.
- [49] V. Vadillo-Rodriguez, J. M. Bruque, A. M. Gallardo-Moreno, M. L. Gonzalez-Martin, *Langmuir* 2013, 29, 8554.
- [50] M. Bergkvist, J. Carlsson, S. Oscarsson, J. Biomed. Mater. Res., Part A 2003, 64, 349.
- [51] M. R. Mozafari, C. J. Reed, C. Rostron, Pharmazie 2007, 62, 205.
- [52] A. M. Reichmuth, M. A. Oberli, A. Jaklenec, R. Langer, D. Blankschtein, *Ther. Delivery* 2016, 7, 319.
- [53] S. Hossen, M. K. Hossain, M. K. Basher, M. N. H. Mia, M. T. Rahman, M. J. Uddin, J. Adv. Res. 2019, 15, 1.
- [54] U. Bulbake, S. Doppalapudi, N. Kommineni, W. Khan, *Pharmaceutics* 2017, 9, 12.
- [55] G. Smistad, J. Jacobsen, S. A. Sande, Int. J. Pharm. 2007, 330, 14.
- [56] M. Halter, M. Antia, V. Vogel, J. Controlled Release 2005, 101, 209.
- [57] D. Ortiz Franyuti, M. Mitsi, V. Vogel, Nano Lett. 2018, 18, 15.
- [58] H. P. Erickson, Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 10114.
- [59] E. M. Chandler, M. P. Saunders, C. J. Yoon, D. Gourdon, C. Fischbach, *Phys. Biol.* **2011**, *8*, 015008.
- [60] G. Baneyx, L. Baugh, V. Vogel, Proc. Natl. Acad. Sci. USA 2002, 99, 5139.
- [61] A. M. Schoepfer, C. Beglinger, A. Straumann, M. Trummler, P. Renzulli, F. Seibold, *Inflammatory Bowel Dis.* 2009, 15, 1851.
- [62] J. W. Jeon, J. I. Lee, H. P. Shin, J. M. Cha, K. R. Joo, S.-H. Kim, I.-G. Ko, J.-J. Jin, S.-E. Kim, C.-J. Kim, *Animal Cells Syst.* **2014**, *18*, 399.
- [63] D. Mehrabani, M. Ziaei, S. V. Hosseini, L. Ghahramani, A. M. Bananzadeh, M. J. Ashraf, A. Amini, M. Amini, N. Tanideh, *Iran Red Crescent Med. J.* 2011, 13, 884.
- [64] H. M. El-Gowelli, E. I. Saad, A. G. Abdel-Galil, E. R. Ibrahim, Toxicol. Appl. Pharmacol. 2015, 288, 300.